$0.51 Earnings Per Share Expected for Innophos Holdings, Inc. (IPHS) This Quarter

Wall Street analysts expect that Innophos Holdings, Inc. (NASDAQ:IPHS) will announce earnings of $0.51 per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Innophos’ earnings. Innophos reported earnings of $0.52 per share during the same quarter last year, which indicates a negative year over year growth rate of 1.9%. The business is scheduled to announce its next earnings results before the market opens on Wednesday, February 20th.

On average, analysts expect that Innophos will report full-year earnings of $2.25 per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of $2.50 per share. Zacks’ EPS averages are an average based on a survey of analysts that cover Innophos.

A number of research firms recently issued reports on IPHS. BidaskClub raised Innophos from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research raised Innophos from a “strong sell” rating to a “hold” rating in a report on Friday, January 4th. Finally, ValuEngine raised Innophos from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James & Associates purchased a new stake in Innophos in the 2nd quarter valued at approximately $209,000. California Public Employees Retirement System boosted its holdings in Innophos by 12.7% in the 2nd quarter. California Public Employees Retirement System now owns 49,220 shares of the specialty chemicals company’s stock valued at $2,343,000 after purchasing an additional 5,558 shares in the last quarter. Northern Trust Corp boosted its holdings in Innophos by 1.5% in the 2nd quarter. Northern Trust Corp now owns 427,388 shares of the specialty chemicals company’s stock valued at $20,342,000 after purchasing an additional 6,446 shares in the last quarter. Dalton Greiner Hartman Maher & Co. boosted its holdings in Innophos by 28.2% in the 3rd quarter. Dalton Greiner Hartman Maher & Co. now owns 95,097 shares of the specialty chemicals company’s stock valued at $4,222,000 after purchasing an additional 20,892 shares in the last quarter. Finally, Deprince Race & Zollo Inc. boosted its holdings in Innophos by 0.3% in the 3rd quarter. Deprince Race & Zollo Inc. now owns 435,140 shares of the specialty chemicals company’s stock valued at $19,320,000 after purchasing an additional 1,464 shares in the last quarter. 93.11% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ IPHS traded up $0.17 during midday trading on Monday, reaching $30.56. 87,600 shares of the company were exchanged, compared to its average volume of 109,756. The company has a quick ratio of 1.36, a current ratio of 2.79 and a debt-to-equity ratio of 1.01. Innophos has a 1 year low of $22.57 and a 1 year high of $50.40. The firm has a market cap of $596.14 million, a P/E ratio of 12.42 and a beta of 1.38.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Recommended Story: Trading signals using Bollinger bands

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit